Castle Biosciences

$CSTL is a diagnostics company improving health through innovative tests that guide patient care. #SkinCancer #UvealMelanoma #BarrettsEsophagus

[Castle Biosciences @CastleBio]

#Top3Words: How would you describe Castle's culture?

EXCITEMENT is one of the words Micah Bires (Digital Marketing Associate) talks about when describing #CastleCulture: "People have such a great energy about what we're doing and people are passionate about the vision of Castle..."

#TeamCastle #CastleCareers #WeLoveOurPeople❤️

[Castle Biosciences @CastleBio]

🎉Congratulations to Dr. Matthew Goldberg, Castle's Senior Vice President of Medical, for being named to the prestigious Power List by The Pathologist for the second year in a row!

The Power List 2026 celebrates the people whose ideas, expertise, and leadership are helping to shape the future of pathology and laboratory medicine. Judges selected the top 50 individuals they believe are doing the most to effect positive change across pathology and laboratory medicine.

The Power List 2026: https://t.co/VRZaBWXMhR

[Castle Biosciences @CastleBio]

#CastleCulture is focused on putting PEOPLE FIRST: patients, clinicians, employees, and investors.

We asked Castle team members: How does your role at Castle make an impact on people? In this video, hear perspectives from Serra Bauer (Area Manager) and Jason March (Senior Product Director), both passionate about how their work with #TissueCypher impacts patients and clinicians.

#PeopleFirst #TeamCastle #CastleCareers #WeLoveOurPeople❤️

[Castle Biosciences @CastleBio]

TOMORROW, 10/14: Castle Biosciences' Chief of Staff Hillary Caruso will be speaking on a panel, "Reimbursement: What Does It Take to Get Paid for Innovation?" at the ASU National Diagnostics Summit (10:45 - 11:30 AM Arizona time). Moderated by Michael Ryan (McDermott Will & Emery), the panel also includes Molly Broache (Illumina), Lena Chaihorsky (Alva10), and Danielle Scelfo (Baylor Genetics).

Registration is free, so join live, either in person at Old Main on the ASU Tempe campus or via Zoom:
https://t.co/fqBZmQRJcM

#ASUDxSummit #Diagnostics #HealthInnovation

[Castle Biosciences @CastleBio]

Castle is presenting NEW DATA from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide additional risk information beyond histopathology to support risk-aligned patient management decisions.

Details/highlights: https://t.co/gpqiArv565

[Matt Gress @MatthewGress]

This week, I was pleased to attend the grand opening of Castle Biosciences’ (@CastleBio) brand-new 55,000 sq. Ft testing laboratory in Scottsdale!

Arizona is at its best when we welcome people willing to take risks, build something, create jobs, and serve others.

Castle’s work represents that commitment.

We are proud to have them in our community and #LD4.

[Castle Biosciences @CastleBio]

#FallIntoHealthyHabits: Ocular Edition

Happy #WorldSightDay! When it comes to staying healthy, we can't forget our 👀 EYES! Many eye diseases, such as uveal melanoma (the most common form of eye cancer), can have no symptoms, so regular exams — including dilated eye exams — are critical to early diagnosis.

#LoveYourEyes #UvealMelanoma #OcularMelanoma #DecisionDxUM

[Castle Biosciences @CastleBio]

🎉We're celebrating! Castle was recently recognized as a Top Workplace in Pittsburgh, ranking 3rd among large companies with more than 400 employees nationally. This recognition is especially meaningful because it reflects the experiences and voices of Castle employees.

As an additional achievement, Castle was honored with the Meaningfulness Award, recognizing our team's outstanding response to the employee engagement survey statement: “My job makes me feel like I am part of something meaningful.”

Representing #TeamCastle: Alicia Angelo, Danyale Strider, and Jamie Bleicher
#TopWorkplaces #CastleCulture

[Castle Biosciences @CastleBio]

#WhyCastle
#TeamCastle members Tabby Smith and Robert Poolsawat weigh in on why they love working at Castle...

"...No matter how big or small your role, we all play a part in making a difference."
"...The culture here is real. It's not just a tagline."

#CastleCulture #CastleCareers #WeLoveOurPeople❤️

[Castle Biosciences @CastleBio]

Castle announces the publication of a study showing that the TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results and de-escalating management for 84% of those with low-risk results.

The study, titled "The Tissue Systems Pathology Test Guides Physician Recommendations for Patients With Non-Dysplastic Barrett's Esophagus: A Case Series From a Gastrointestinal Surgery Center," was published in Foregut: The Journal of the American Foregut Society and is linked in the press release: https://t.co/tLhVCu2cos

[Castle Biosciences @CastleBio]

Castle announces the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection.

"One thing came through clearly in this study: patients want better control of their disease and more information to help guide their treatment decisions," said study author Diego Ruiz Dasilva, M.D., board-certified dermatologist at Forefront Dermatology in Virginia Beach, Virginia. "AdvanceAD-Tx gives us an opportunity to bring objective molecular information into those conversations, helping personalize systemic treatment decisions and expedite the path to an effective therapy and symptom relief."

Press Release: https://t.co/Gn92xtoAH1

[Castle Biosciences @CastleBio]

In case you needed any more reasons to get moving, physical activity has been inversely associated with the risk of several cancers (including esophageal cancer and esophageal adenocarcinoma), according to a study in BMC Gastroenterology.

Read full study: https://t.co/tmPhN6udNO

#FallIntoHealthyHabits #EsophagealCancer #EAC

[Castle Biosciences @CastleBio]

Another beautiful day for a walk, this time in Nashville at the recent Steps Against Melanoma Walk, which helped to honor loved ones, support those currently facing melanoma, and raise awareness about one of the most aggressive forms of skin cancer. Leah Eaton represented #TeamCastle, proud to support @AIMatMelanoma in fueling critical research, raising awareness, and empowering the community in the fight against #melanoma. #FallIntoHealthyHabits #CastleCares

[Castle Biosciences @CastleBio]

Castle announces the opening of its new laboratory and office facility in Scottsdale, Arizona, and will commemorate the milestone with a grand opening celebration at the new facility, located at 8667 E. Hartford Drive, on Tuesday, October 6, 2026, at 3:30 pm MST. The new 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth.

Press release: https://t.co/hQijB7912N

[Castle Biosciences @CastleBio]

Fall is the perfect time to get outside and walk to support those affected by melanoma and raise awareness about one of the most aggressive forms of skin cancer. Castle was proud to support @AIMatMelanoma at their recent Steps Against Melanoma Walk in Louisville, helping to advance education, fund innovative research, and provide hope to melanoma patients and families across the country.

Representing #TeamCastle: CarolAnn Motley and Louise Burke
#FallIntoHealthyHabits #CastleCares

[Castle Biosciences @CastleBio]

Castle announces the publication of a new decision modeling study showing that the TissueCypher Barrett's Esophagus test (TSP-9) can help better align Barrett's esophagus (BE) management with a patient's individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).

Full press release: https://t.co/99WLbfc8ue

[Castle Biosciences @CastleBio]

TOMORROW: Castle's executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 am ET. Details/registration: https://t.co/69pA5whsuy

[Castle Biosciences @CastleBio]

We're ECSTATIC to have won more (consecutive) Top Workplaces awards!

🏆Healthcare Industry Top Workplace — 4th year in a row
🏆Arizona Top Workplace — 5th year in a row
🏆8 Culture Excellence Awards — Leadership, Professional Development, Purpose & Values, Work-Life Flexibility, Employee Appreciation, Compensation & Benefits, Employee Well-Being, and Innovation

Castle also earned a 2026 Top Workplaces USA award earlier this year.
#CastleCulture #TopWorkplaces #WeLoveOurPeople❤️

[Castle Biosciences @CastleBio]

Castle Biosciences today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC). The study, titled "Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma," evaluated the enhanced DecisionDx-SCC algorithm in an independent validation cohort of 572 patients with high-risk SCC.

Press release: https://t.co/XpNIbXhWFA

[Castle Biosciences @CastleBio]

☀️Sun safety doesn't end with summer months, so keep your student sun-safe at school!

#FallIntoHealthyHabits & #PracticeSafeSun by covering up/layering clothing and wearing sunscreen (clothing is the single most effective form of sun protection for the body).

More #BackToSchool sun safety tips from The Skin Cancer Foundation @SkinCancerOrg: https://t.co/hM0jlHcrUS